Facebook Instagram Twitter Linkedin Youtube Podcast

Duchenne News Tags: NS Pharma

Search
Tags
Tags
Antisense Therapeutics Astellas Pharma Avidity Biosciences BioMarin Pharmaceuticals Capricor Therapeutics Catalyst Pharmaceuticals Dyne Therapeutics Edgewise Therapeutics Entrada Therapeutics FDA FibroGen Italfarmaco ITF Therapeutics NS Pharma PepGen Pfizer Pliant Therapeutics PTC Therapeutics REGENXBIO Santhera Sarepta Therapeutics Solid Biosciences Wave Life Sciences
November 21, 2023

NS Pharma Releases We Speak Duchenne Educational Website

NS Pharma shares new educational platform, We Speak Duchenne.
Read More
April 18, 2023

NS Pharma Announces FDA Clearance to Initiate Phase II Study for NS-089/NCNP-02, an Exon 44 Skipping Candidate for the Treatment of Duchenne

NS Pharma announces FDA agreed to planned Phase II study of NS-089/NCNP02 for Duchenne.
Read More
NS Pharma
June 2, 2022

NS Pharma: Long-Term Efficacy and Safety Data of Viltolarsen Published in the Journal of Neuromuscular Diseases

On May 31, 2022, NS Pharma shared a press release on the 2-y interim analysis from the study of viltolarsen.
Read More

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | [email protected]

Gold Transparency 2022 Candid. Logo
Sitemap
© 2024 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*) 

Register Now

Experience the magic this summer!

Apply Today

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Register Today

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Give Today

Accessible Vehicle Fund Applications Open

Apply Today